pharmaceutical industry

Pfizer Stock (PFE) Slides After 2026 Guidance: COVID Sales Drop, Patent Cliff and Analyst Forecasts in Focus

Pfizer Inc. (NYSE: PFE) shares fell sharply in U.S. trading on Tuesday, December 16, 2025, as investors weighed the drugmaker’s first look at full-year 2026 guidance, an updated 2025 revenue outlook, and fresh commentary on cost savings and capital allocation.

16 December 2025

Pfizer Forecasts Flat 2026 Sales and Lower Profit as COVID Demand Falls; PFE Dividend Remains $0.43

Pfizer’s latest outlook is setting the tone for how investors may view the drugmaker’s post-pandemic transition in 2026: steady underlying growth ambitions, but a near-term financial “air pocket” as COVID-19 revenue continues to shrink and several products face patent and

16 December 2025

COVID-19 · Dividends · Financial News · NYSE:PFE · Pharmaceuticals · Stock Market

GSK plc Stock News Today (Dec. 13, 2025): EU and FDA Decisions Put Pipeline Momentum Back in Focus

Updated: December 13, 2025 GSK plc (LSE: GSK, NYSE: GSK) is ending the week in the spotlight after a cluster of regulatory updates in Europe and the United States—exactly the kind of “catalyst stacking” that can shift the narrative around

13 December 2025

GSK News · Investment Insights · Pharma Industry · Regulatory Updates · Stock Market

GSK’s Emma Walmsley Hails US as ‘Best Place to Invest’ as UK Pharma Faces Tariffs, Rebate Cuts and a Fight for Jobs

On 11 December 2025, outgoing GSK chief executive Dame Emma Walmsley sent a stark message to Westminster and the City: for big drug makers, the United States is now the premier destination for investment – and Britain is at risk

11 December 2025

Business News · Healthcare Policy · Investment · NYSE:AZN · NYSE:GSK · Pharma Industry · UK Economy

GSK Stock (LON:GSK, NYSE:GSK): Latest News, FDA Catalysts and 2026 Outlook – December 11, 2025

GSK plc stock has quietly morphed from a problem child of Big Pharma into one of 2025’s more interesting “value with growth” stories. The shares are trading near multi‑year highs, the company has upgraded guidance, big litigation overhangs are easing,

11 December 2025

FDA Updates · Healthcare Industry · Investment Outlook · Market News · Pharmaceutical Stocks

Merck Stock (MRK) Today – Keytruda Developments, Analyst Price Targets and 2025–2026 Forecast

Merck & Co., Inc. (NYSE: MRK) is back in the spotlight as Wall Street raises price targets, new clinical data hit the tape, and a wave of product approvals and partnerships reshapes the outlook for its blockbuster cancer franchise Keytruda

10 December 2025

Financial Forecasts · Healthcare Industry · Investment Analysis · NYSE:MRK · Pharmaceuticals · Stock Market

Eli Lilly’s $6 Billion Huntsville Plant: 450 High‑Paying Jobs, GLP‑1 Drug Boom and Alabama’s Biggest Industrial Bet

HUNTSVILLE, Ala. — December 9, 2025 Eli Lilly and Company will invest more than $6 billion in a new advanced pharmaceutical manufacturing campus in Huntsville, Alabama, creating 450 high‑value permanent jobs and an estimated 3,000 construction jobs in what state

10 December 2025

Alabama · Business · Industry · Jobs · NYSE:LLY · Pharmaceuticals

Eli Lilly Stock (LLY) on December 9, 2025: Price, Alabama Megaplant, Jaypirca Breakthrough and 2026–2030 Forecasts

As of Tuesday, December 9, 2025, Eli Lilly (NYSE: LLY) sits at the center of nearly every conversation about obesity drugs, oncology breakthroughs and “next trillion‑dollar” stocks. The shares trade around $980 per share, down about 1.6% on the day but

9 December 2025

Company News · Investment Insights · Market Forecasts · NYSE:LLY · Pharmaceutical Industry · Stock Analysis

Eli Lilly (LLY) Stock Outlook: Can the Obesity-Drug Giant Keep Justifying a $1,000 Share Price?

Updated: December 5, 2025 Eli Lilly and Company (NYSE: LLY) remains one of the most closely watched stocks in global markets as investors weigh eye‑popping growth in obesity and diabetes drugs against equally eye‑popping valuations and rising political pressure on

5 December 2025

Company Analysis · Financial News · Investing · Pharmaceuticals · Stock Market

Bristol Myers Squibb (BMY) Stock Today: Cobenfy Trial Twist, AI Drug Discovery Milestone and $6.7 Billion Lawsuit Shape the 2026 Outlook

As of December 4, 2025, Bristol Myers Squibb Company (NYSE: BMY) is back on the radar of growth, value and dividend investors. After a sharp rally this week driven by fresh news on its Alzheimer’s drug Cobenfy, an AI-enabled drug

4 December 2025

AI Technology · Investment Analysis · Legal News · NYSE:BMY · Pharmaceuticals · Stock Market

Johnson & Johnson (JNJ) Stock on December 3, 2025: Analyst Upgrades, Options Signals and New Drug Wins at Near‑Record Highs

Johnson & Johnson (NYSE: JNJ) is trading around $205–$206 per share on Wednesday, December 3, 2025, just shy of its 52‑week high of about $207.81, after a powerful rally that has lifted the stock roughly 40% this year. MarketBeat+2ChartMill+2 Today’s

4 December 2025

Analyst Ratings · Financial News · Investing · NYSE:JNJ · Pharmaceuticals · Stock Market

Sun Pharma Advanced Research (SPARC) Stock Soars After US Court Ruling on Sezaby PRV – What the 30% Two‑Day Rally on 3 December 2025 Really Means

SPARC stock on 3 December 2025: Still volatile after a 2‑day surge Sun Pharma Advanced Research Company Ltd (SPARC) has exploded back onto traders’ screens this week. On 2 December 2025, the stock hit the 20% upper circuit at around

3 December 2025

Court Rulings · Financial News · Investment Analysis · Pharma Industry · Stock Market